Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;45(2):261-273.
doi: 10.1007/s40618-021-01666-6. Epub 2021 Aug 29.

The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis

J J Ge #  1 , D J Wang #  2 , W Song  1 , S M Shen  3 , W H Ge  4
Affiliations
Review

The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis

J J Ge et al. J Endocrinol Invest. 2022 Feb.

Abstract

Purpose: The purpose of this study is to evaluate the effectiveness and safety of liraglutide/liraglutide + metformin in overweight/obese women with polycystic ovary syndrome (PCOS).

Methods: The related literatures published until April 2021 were searched in PubMed, Cochrane Library, MEDLINE and EmBase.

Results: Six randomized controlled trials of 127 related articles were obtained through searching. Three articles compared liraglutide with metformin, and four articles compared liraglutide combined with metformin with metformin. Our meta-analysis suggests that liraglutide was superior to metformin only in weight loss [MD = - 2.74, 95% CI (- 4.29, - 1.18), P = 0.0006]. Compared with metformin group, the combination group had significant advantages in weight loss [MD = - 3.81, 95% CI (- 5.16, - 2.46), P < 0.001], BMI [MD = - 2.59, 95% CI (- 3.12, - 2.07), P < 0.001], waist circumference [MD = - 6.26, 95% CI (- 7.79, - 4.72), P < 0.001], fasting blood glucose [MD = - 0.59, 95% CI (- 0.74, - 0.44), P < 0.001] and fasting insulin [MD = - 1.52, 95% CI (- 2.69, - 0.35), P = 0.01], while the incidence of adverse reactions was relatively high [RR = 2.91, 95% CI (1.55, 5.46), P = 0.00009].

Conclusion: The present results indicate that liraglutide and metformin have the similar effects in the treatment of overweight/obese PCOS patients. Liraglutide combined with metformin is more effective than metformin in improving PCOS, but it is necessary to master the correct medication method to reduce the occurrence of adverse reactions.

Keywords: Effectiveness; Liraglutide; Meta-analysis; Metformin; Polycystic ovary syndrome; Safety.

PubMed Disclaimer

References

    1. Paschou SA, Polyzos SA, Anagnostis P, Goulis DG, Kanaka-Gantenbein C et al (2020) Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Endocrine 67:1–8 - PubMed
    1. Norman RJ, Dewailly D, Legro RS, Hickey TE (2007) Polycystic ovary syndrome. Lancet 370:685–697 - PubMed
    1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised (2003) consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25
    1. Mahalingaiah S, Diamanti-Kandarakis E (2015) Targets to treat metabolic syndrome in polycystic ovary syndrome. Expert Opin Ther Targets 19:1561–1574 - PubMed - PMC
    1. Zeng X, Xie YJ, Liu YT, Long SL, Mo ZC (2020) Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta 502:214–221 - PubMed

MeSH terms

LinkOut - more resources